Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

Republican candidates in one of the nation's most hotly contested Senate races are pushing the bounds of high-dollar politicking, an Axios examination shows.

Why it matters: Anti-corruption rules bar candidates from coordinating with supportive super PACs. In Ohio's GOP Senate primary, huge amounts of money are pouring in, and operatives are finding creative ways to leverage it without breaking federal law.

What's happening: The latest ostensibly independent group to enter the fray, a super PAC called Ohio Leads, is backing former state GOP chair Jane Timken.

  • It was officially formed in September, and this week reported spending more than $220,000 on pro-Timken digital ads.
  • In advertising disclosures on Facebook, the group lists a phone number associated with a Republican operative who advises the Ricketts family, which includes some of the GOP's top donors.
  • Late last month — after Ohio Leads was formed but before it began running ads — the Timken campaign held a fundraiser at the Ricketts residence, according to an invitation obtained by Axios.
  • Two sources familiar with the event told Axios it was organized by Sylvie Légère, the wife of then-Republican National Committee finance chair Todd Ricketts, who did not attend the event to avoid the appearance of favoritism in his RNC position.

The intrigue: Ohio Leads' ads use footage from a five-minute b-roll clip uploaded to the Timken campaign's YouTube page late last month.

  • Source code indicates the Republican consulting firm Majority Strategies helped build websites for both Ohio Leads and the Timken campaign.
  • The campaign has paid Majority Strategies more than $70,000 this year for literature production, graphic design and digital ads, according to Federal Election Commission records.

How it works: The b-roll maneuver is a common way for campaigns to boost supportive independent spenders without violating laws barring campaign-super PAC coordination.

  • Campaigns frequently upload those sorts of clips to locations where allied super PACs can find and download them to use in their own ads.
  • It's also legal for vendors to work with both a campaign and a group it's legally barred from working with, as long as they establish internal firewalls between that work.

What they're saying: "Of course, Jane’s campaign has no coordination with any outside effort and follows the letter and intent of the law to the letter," Timken spokesperson Mandi Merritt told Axios in an emailed statement.

  • “We are incredibly excited Jane has outside support from donors who recognize she is the only true America First candidate with the grassroots strength and record of conviction to stop Joe Biden and the Radical Left," Merritt wrote.

Timken is not the only candidate in the race benefiting from that sort of super PAC vendor overlap.

  • Primary rival Josh Mandel is working with prominent GOP consultancy Axiom Strategies.
  • That firm also is helping to air ads from a pro-Mandel super PAC, the USA Freedom Fund.
  • The firm previously told Axios it established firewalls to ensure it does not run afoul of coordination rules.

The big picture: Timken and Mandel are both competing against a candidate, "Hillbilly Elegy" author J.D. Vance, whose super PAC is backed by $10 million from billionaire tech investor Peter Thiel.

  • The race is expected to be one of the most expensive in the country, during a midterm cycle that will likely break election spending records.

Go deeper

Ohio lawmakers pass new congressional district map

This Ohio congressional map is poised to be in place for the 2022 and 2024 election cycles. Photo courtesy of state legislature

Amid Democratic complaints of gerrymandering, Republicans in the Ohio House of Representatives approved a new congressional district map yesterday.

Why it matters: Thursday's vote is the latest important step in a lengthy process to shape Ohio's political representation in Washington, D.C.

New Zealand aims to create smoke-free generation with tobacco ban

New Zealand Prime Minister Jacinda Ardern at a December news conference in Auckland, New Zealand. Photo: Phil Walter/Getty Images

New Zealand officials announced Thursday legislative plans to outlaw smoking by making it illegal to sell or supply tobacco products to the next generation as part of a lifetime ban.

Why it matters: "People aged 14 when the law comes into effect will never be able to legally purchase tobacco," Associate Health Minister Ayesha Verrall said in a statement announcing the proposed law, part of the Smokefree 2025 Action Plan.

FDA approves AstraZeneca COVID drug for people with immune problems

Photo: Qilai Shen/Bloomberg via Getty Images

The Food and Drug Administration issued an emergency use authorization for an AstraZeneca COVID-19 antibody drug for people with compromised immune systems.

Why it matters: The drug, Evusheld, is the first antibody therapy authorized in the U.S. to prevent coronavirus symptoms before virus exposure.